Company intelligence / Profile preview
SunRegen Healthcare AG
Reinach, Basel-Land, Switzerlandsunregen.ch ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
SunRegen is developing SBC003, a compound showing neuroprotective and neuro-rescuing effects in multiple models. One blind patient has been successfully treated with an SBC003 precursor. The compound has shown efficacy in 5 species, 10 toxins, and 20+ models[1][6].
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- Small molecules (SBC003)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on SunRegen Healthcare AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SunRegen Healthcare AG.